Table S1 Factors associated with OS in patients with stage IIB thymoma before PSM

Factors	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
Age				
<65 years	1.000 (reference)		1.000 (reference)	
≥65 years	3.686 (2.204, 6.166)	<0.001	4.644 (2.705, 7.971)	<0.001
Gender				
Male	1.000 (reference)		–	–
Female	0.831 (0.503, 1.370)	0.46	–	–
Race				
White	1.000 (reference)		–	–
Black	0.989 (0.445, 2.198)	0.97	–	–
Others	0.682 (0.352, 1.321)	0.25	–	–
WHO histology				
Low risk	1.000 (reference)		1.000 (reference)	
High risk	1.848 (1.007, 3.389)	0.047	2.407 (1.292, 4.484)	0.006
NOS	1.668 (0.903, 3.081)	0.10	1.880 (1.005, 3.517)	0.048
Chemotherapy				
No	1.000 (reference)		1.000 (reference)	
Yes	1.136 (0.337, 3.828)	0.83	1.713 (0.496, 5.912)	0.39
Unknown	1.682 (0.953, 2.967)	0.07	2.110 (1.174, 3.793)	0.01
Tumor size				
<5.5 cm	1.000 (reference)		–	–
≥5.5 cm	1.032 (0.603, 1.767)	0.90	–	–
Unknown	0.523 (0.122, 2.241)	0.38	–	–
PORT				
No	1.000 (reference)		1.000 (reference)	
Yes	0.919 (0.551, 1.532)	0.74	1.150 (0.677, 1.952)	0.60

OS, overall survival; PSM, propensity score matching; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; NOS, not otherwise specified; PORT, postoperative radiotherapy.

Table S2 Factors associated with CSS in patients with stage IIB thymoma before PSM

Factors	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
Age				
<65 years	1.000 (reference)		–	–
≥65 years	1.581 (0.442, 5.654)	0.48	–	–
Gender				
Male	1.000 (reference)		–	–
Female	1.024 (0.296, 3.541)	0.97	–	–
Race				
White	1.000 (reference)		–	–
Black	2.188 (0.441, 10.845)	0.33	–	–
Others	0.931 (0.188, 4.614)	0.93	–	–
WHO histology				
Low risk	1.000 (reference)		1.000 (reference)	
High risk	1.209 (0.202, 7.238)	0.83	1.156 (0.187, 7.162)	0.87
NOS	3.113 (0.742, 13.052)	0.12	2.686 (0.634, 11.386)	0.18
Chemotherapy				
No	1.000 (reference)		1.000 (reference)	
Yes	3.913 (0.352, 43.522)	0.26	3.414 (0.297, 39.287)	0.32
Unknown	3.252 (0.646, 16.379)	0.15	2.603 (0.500, 13.557)	0.25
Tumor size				
<5.5 cm	1.000 (reference)		–	–
≥5.5 cm	1.873 (0.389, 9.028)	0.43	–	–
Unknown	2.764 (0.249, 30.652)	0.40	–	–
PORT				
No	1.000 (reference)		1.000 (reference)	
Yes	2.331 (0.495, 10.979)	0.28	2.159 (0.455, 10.237)	0.33

CSS, cancer-specific survival; PSM, propensity score matching; HR, hazard ratio; CI, confidence interval; WHO, World Health Organization; NOS, not otherwise specified; PORT, postoperative radiotherapy.

Table S3 Baseline characteristics before and after PSM for Asians

Characteristics	Before PSM			After PSM		
	Non-PORT (n=23), n (%)	PORT (n=38), n (%)	P	Non-PORT (n=18), n (%)	PORT (n=18), n (%)	P
Age			0.34			>0.99
<65 years	15 (65.2)	29 (76.3)		14 (77.8)	14 (77.8)	
≥65 years	8 (34.8)	9 (23.7)		4 (22.2)	4 (22.2)	
Gender			0.19			>0.99
Male	10 (43.5)	23 (60.5)		8 (44.4)	8 (44.4)	
Female	13 (56.5)	15 (39.5)		10 (55.6)	10 (55.6)	
WHO histology			0.39			0.33
Low risk	12 (52.2)	15 (39.5)		7 (38.9)	8 (44.4)	
High risk	5 (21.7)	15 (39.5)		5 (27.8)	8 (44.4)	
NOS	6 (26.1)	8 (21.1)		6 (33.3)	2 (11.1)	
Chemotherapy			0.91			>0.99
No	15 (65.2)	23 (60.5)		11 (61.1)	12 (66.7)	
Yes	2 (8.7)	3 (7.9)		1 (5.6)	0 (0.0)	
Unknown	6 (26.1)	12 (31.6)		6 (33.3)	6 (33.3)	
Tumor size			0.81			>0.99
<5.5 cm	8 (34.8)	16 (42.1)		7 (38.9)	7 (38.9)	
≥5.5 cm	14 (60.9)	20 (52.6)		10 (55.6)	10 (55.6)	
Unknown	1 (4.3)	2 (5.3)		1 (5.6)	1 (5.6)	

PSM, propensity score matching; PORT, postoperative radiotherapy; NOS, not otherwise specified.